Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil.
Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Centre of Health Sciences, Federal University of Rio Grande do Norte-UFRN, Natal 59012-570, Brazil.
Int J Mol Sci. 2023 Sep 7;24(18):13778. doi: 10.3390/ijms241813778.
Chagas disease is a neglected tropical disease caused by the protozoan . Benznidazole and nifurtimox are the two approved drugs for their treatment, but both drugs present side effects and efficacy problems, especially in the chronic phase of this disease. Therefore, new molecules have been tested with promising results aiming for strategic targeting action against . Several studies involve in vitro screening, but a considerable number of in vivo studies describe drug bioavailability increment, drug stability, toxicity assessment, and mainly the efficacy of new drugs and formulations. In this context, new drug delivery systems, such as nanotechnology systems, have been developed for these purposes. Some nanocarriers are able to interact with the immune system of the vertebrate host, modulating the immune response to the elimination of pathogenic microorganisms. In this overview of nanotechnology-based delivery strategies for established and new antichagasic agents, different strategies, and limitations of a wide class of nanocarriers are explored, as new perspectives in the treatment and monitoring of Chagas disease.
恰加斯病是一种被忽视的热带病，由原生动物引起。苯硝唑和硝呋替莫是两种已批准用于治疗该病的药物，但这两种药物都存在副作用和疗效问题，尤其是在该病的慢性期。因此，已经测试了一些新的分子，结果令人鼓舞，这些分子旨在针对进行战略靶向作用。一些研究涉及体外筛选，但相当多的体内研究描述了药物生物利用度的提高、药物稳定性、毒性评估，以及主要是新药和制剂的疗效。在这种情况下，已经开发了新的药物输送系统，如纳米技术系统，用于这些目的。一些纳米载体能够与脊椎动物宿主的免疫系统相互作用，调节免疫反应，以消除致病微生物。在这篇关于基于纳米技术的现有和新型抗恰加斯病药物输送策略的综述中，探讨了广泛的纳米载体的不同策略和局限性，为恰加斯病的治疗和监测提供了新的视角。
Zotero 插件
